MKM Partners Reiterates Bullish Stance on Nektar Therapeutics (NKTR); Phase 3 to Start this Month
Tweet Send to a Friend
MKM Partners reiterated its Buy rating and $13 price target on Nektar Therapeutics (NASDAQ: NKTR) Thursday after the company presented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
